Podcast: Is Remdesivir Approvable? DARPA's Race To Find An Antibody ‘Firebreak’ Plus Pharma's Pandemic Q1s
Analysis On Pharma In The Time Of COVID-19
A review of developments including Gilead's imminent 'big reveal' of remdesivir data and how big pharma has fared financially in the first three months of 2020.
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
FDA indicates it expects sponsors and other government agencies to come up with ways to fulfill its request for placebo-controlled studies post-emergency use authorization of COVID-19 vaccines, but neither it nor vaccines advisory committee see a clear way to do this.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.